GlassScriptPhysician profile
Maria Lisa Lambert
NPI 1184600272
$714.47
in general payments reported to CMS, 2019-2025
13 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2021: $42.02 · 2022: $31.36 · 2023: $44.54 · 2024: $130 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473 · Education: $40.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $472.86 |
| Education | $40.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $122.16 | 2023-2025 | |
| Lilly USA, LLC | $112.01 | 2024-2025 | Zepbound |
| Therapeuticsmd, INC. | $78.05 | 2019-2022 | |
| Astellas Pharma US INC | $73.02 | 2024-2025 | Veozah |
| Millicent US INC | $55.02 | 2024-2025 | Femring, Intrarosa |
| Abbvie INC. | $50.50 | 2019-2024 | |
| Acella Pharmaceuticals, LLC | $50.03 | 2024-2025 | NP Thyroid 60 |
| Novo Nordisk INC | $47.55 | 2019-2025 | Wegovy |
| Coopersurgical, INC. | $33.58 | 2019 | |
| Currax Pharmaceuticals LLC | $32.26 | 2025 | Contrave |
| Evofem Biosciences, INC. | $30.26 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.83 | 2025 | Xifaxan |
| Exeltis, USA INC. | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.